Crinetics Pharmaceuticals Stock Investor Sentiment
| CRNX Stock | USD 57.20 0.47 0.81% |
Slightly above 70% of Crinetics Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Crinetics Pharmaceuticals suggests that many traders are alarmed. Crinetics Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Crinetics Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Panic Vs Confidence
30
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Crinetics Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Crinetics Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Crinetics Historical Sentiment
Although Crinetics Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Crinetics, such as negative comments on social media and news outlets, may cause fear in the market and push Crinetics Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Crinetics.
Crinetics |
Crinetics Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Crinetics Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Crinetics Pharmaceuticals Historical Investor Sentiment
Investor biases related to Crinetics Pharmaceuticals' public news can be used to forecast risks associated with an investment in Crinetics. The trend in average sentiment can be used to explain how an investor holding Crinetics can time the market purely based on public headlines and social activities around Crinetics Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Crinetics Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Crinetics Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Crinetics Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Crinetics Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about Crinetics Pharmaceuticals that are available to investors today. That information is available publicly through Crinetics media outlets and privately through word of mouth or via Crinetics internal channels. However, regardless of the origin, that massive amount of Crinetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Crinetics Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Crinetics Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Crinetics Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Crinetics Pharmaceuticals alpha.
Crinetics Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly | 09/26/2024 |
2 | Disposition of 14375 shares by Pizzuti Dana of Crinetics Pharmaceuticals at 54.63 subject to Rule 16b-3 | 10/03/2024 |
3 | Crinetics Pharmaceuticals Sees Strong Trading Volume Heres Why | 10/11/2024 |
4 | State Street Corps Strategic Acquisition in Crinetics Pharmaceuticals | 10/17/2024 |
5 | Crinetics Pharmaceuticals to Release Quarterly Earnings on Tuesday | 11/05/2024 |
6 | Wellington Management Group LLP Reduces Stake in Crinetics Pharmaceuticals Inc | 11/08/2024 |
7 | Crinetics Pharmaceuticals GAAP EPS of -0.96 misses by 0.05 | 11/12/2024 |
8 | Crinetics Pharmaceuticals, Inc. Q3 2024 Earnings Call Transcript | 11/13/2024 |
9 | Crinetics Pharmaceuticals Announces Earnings Results, Misses Estimates By 0.05 EPS | 11/14/2024 |
10 | EcoR1 Capital, LLC Reduces Stake in ITeos Therapeutics Inc | 11/15/2024 |
11 | Acquisition by Marc Wilson of 25000 shares of Crinetics Pharmaceuticals at 20.02 subject to Rule 16b-3 | 11/21/2024 |
12 | Disposition of 501 shares by Jeff Knight of Crinetics Pharmaceuticals at 56.52 subject to Rule 16b-3 | 11/22/2024 |
13 | Insider Selling Crinetics Pharmaceuticals, Inc. COO Sells 501 Shares of Stock | 11/29/2024 |
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.